Daily Aspirin Does Not Lower Colorectal Cancer Risk, Review Finds

A Critical appraisal of aspirin for colorectal cancer prevention: design, scope, and limitations

• The topic centers on whether daily, low-dose aspirin reduces colorectal cancer risk in populations without genetic predisposition or prior colorectal cancer.
• The source notes colorectal cancer as a major global health burden, with 2022 WHO-reported figures of 1.9 million new cases and over 900,000 deaths, and acknowledges rising incidence among younger age groups in some regions.
• Prior observations in the literature suggested potential preventive benefits of aspirin in certain at-risk groups, including those with genetic susceptibility or a history of colorectal cancer, but the applicability to average-risk individuals remains contested.

• The content summarizes a qualitative synthesis of ten trials, totalling nearly 125,000 participants, conducted in older adults and comparing aspirin against placebo or no intervention.
• Eligible trials focused on primary colorectal cancer or colorectal adenoma outcomes, with follow-up periods ranging from five years to more than 15 years.
• Trial populations were predominantly white, with participant mean ages spanning roughly 53 to 71 years.
• The aspirin regimens across studies varied: most used a low daily dose of 75–100 mg, while a subset employed higher daily doses up to 500 mg.
• The primary outcomes captured included incidence of colorectal cancer within the follow-up window; several trials also tracked colorectal cancer–related mortality, and a subset documented serious adverse events associated with aspirin, notably bleeding events.

Specifically, extracranial hemorrhage and hemorrhagic stroke were highlighted as adverse events more likely with aspirin exposure in the included studies.

The analysis challenges the notion of a blanket recommendation for aspirin use to prevent bowel cancer in unselected populations.

• Across the included trials, daily aspirin did not demonstrate a reduction in the risk of primary colorectal cancer or colorectal adenomas in non-genetically predisposed adults without prior colorectal cancer.
• Six of the analyzed studies contributed data on mortality related to colorectal cancer, though the summary does not specify a consistent mortality signal; the emphasis remains on cancer incidence outcomes.
• Regarding safety, the evidence indicated that aspirin use had little effect on overall serious adverse events but was associated with an increased likelihood of certain bleeding complications.
• The authors emphasize heterogeneity in trial designs, dosing regimens, and populations, which complicates definitive conclusions about a universal preventive role for aspirin in colorectal cancer.

This would rely on molecular markers and individual risk profiles to identify subgroups that might derive net benefit from aspirin, balancing potential cancer prevention against bleeding risks.

• The authors contrast the role of aspirin in cardiovascular prevention, where low-dose daily aspirin is standard for individuals with existing cardiovascular risk, against the absence of a clear cancer-prevention signal in the general population without cardiovascular disease.
• They underscore a need to move away from one-size-fits-all guidance and advocate for precision prevention approaches.

• The review implies that routine, population-wide daily aspirin for colorectal cancer prevention is not supported by the current body of high-quality trial evidence.
• In populations without cardiovascular disease, the bleeding risk associated with daily aspirin may outweigh potential, uncertain cancer-preventive benefits.
• The finding reinforces the importance of non-pharmacologic strategies for colorectal cancer risk reduction, such as maintaining a healthy lifestyle and adhering to screening recommendations, rather than relying on aspirin as a preventive measure for colorectal cancer alone.

• The summary notes uncertainty due to study-level heterogeneity, including variations in aspirin dose, duration of exposure, and follow-up lengths.
• The patient cohorts were predominantly older, white adults, which may limit generalizability to more diverse populations.
• While six trials reported colorectal cancer–specific mortality, the overall editorial does not provide explicit pooled effect estimates or statistical significance for cancer outcomes, leaving some ambiguity about the magnitude of any potential, non-significant signals.
• The authors explicitly acknowledge that the evidence base does not support a universal recommendation for aspirin for colorectal cancer prevention in the absence of prior cancer or genetic risk.

• Identification of molecular or risk-stratified subgroups that could benefit from aspirin for colorectal cancer prevention remains a priority.
• Future investigations could clarify dose–response relationships, optimal exposure duration, and stratification by baseline bleeding risk to inform precision prevention strategies.
• Additional research in more diverse populations would help determine the external validity of current findings.